NCT02632448
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02632448
Title A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Esperas Pharma Inc.
Indications
Therapies
Age Groups: adult
Covered Countries USA | POL | HRV | CAN

Facility Status City State Zip Country Details
Dana Farber Cancer Institute Boston Massachusetts 02215 United States Details
Karmanos Cancer Institute Detroit Michigan 48201 United States Details
Tom Baker Cancer Centre Calgary Alberta T2N 4N2 Canada Details
Cross Cancer Institute Edmonton Alberta T6G 1Z2 Canada Details
BC Cancer Agency Vancouver British Columbia V5Z 4E6 Canada Details
Ottawa Hospital Cancer Centre Ottawa Ontario K1H 8L6 Canada Details
University Health Network - Princess Margaret Hospital Toronto Ontario M5G 2M9 Canada Details
Centre Hospitalier de l'Université de Montréal Montreal Quebec H2X 0A9 Canada Details
Jewish General Hospital Montreal Quebec H3T 1E2 Canada Details
McGill University Health Centre Montreal Quebec H4A 3J1 Canada Details
General Hospital Zadar Zadar 23000 Croatia Details
University Hospital Centre Zagreb Zagreb 10000 Croatia Details
Centrum Onkologii im. prof. F. Łukaszczyka Bydgoszcz 85-796 Poland Details
Uniwersyteckie Centrum Kliniczne Osrodek Badan Klinicznych Wczesnych Faz Gdansk 80-214 Poland Details
Centrum Badań Klinicznych Jagiellońskie Centrum Innowacji sp. z o. o. Krakow 30-348 Poland Details
Szpital Specjalistyczny im. L. Rydygiera w Krakowie sp. z o. o. Krakow 31-826 Poland Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field